In addition, 1p19q no-codeletion (Figure 6C), IDH1 wildtype (Figure 6D), MGMT un-methylated (Figure 6E), and recurrent glioma (Figure 6F) compared with 1p19q deletion (Figure 6C), IDH1 mutant (Figure 6D), MGMT methylated (Figure 6E), and primary glioma (Figure 6F), AP001007.1, LBX-AS1, and MIR155HG also was high expression, while MAPT-AS1 and LINC00515 were also low in CGGA (except for LINC00515 in Figure 6E and MAPT-AS1 in Figure 6F, p > 0.05). The gene discussed is MAPT; the disease is central nervous system cancer.